Liraglutide
5 mg
GLP-1 Analogue (Saxenda/Victoza analogue)
Liraglutide
First-generation GLP-1 analogue for established metabolic research protocols.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
Liraglutide is a well-established GLP-1 receptor agonist with extensive published research. It shares 97% homology with native human GLP-1 and has been one of the most widely studied peptides in metabolic research. Its established safety and efficacy profile makes it a common reference compound.
Specifications
- SKU
- LIRA-5MG
- Size
- 5 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Liraglutide has been extensively studied in both preclinical and clinical settings. Research demonstrates activation of GLP-1 receptors in pancreatic beta cells and CNS appetite centres. Its acylation with a C16 fatty acid enables albumin binding, extending its half-life to approximately 13 hours.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)